AI-Stroke, SAS

AI-Stroke, SAS is a French company focused on developing AI-driven solutions for stroke detection and diagnosis, enhancing pre-hospital care and empowering first responders with crucial diagnostic tools. Founded in 2022 and headquartered in Montpellier, France, AI-Stroke, SAS specializes in AI technologies that facilitate stroke diagnosis. The company has secured a total of USD 4. 6 mn through a SEED funding round on November 7, 2025, led by Newfund, with participation from Bpifrance Investissement.

AI-Stroke specializes in innovative AI-powered solutions aimed at enhancing the detection and diagnosis of stroke in pre-hospital settings. The company’s flagship product is a mobile application designed to function as a digital neurologist, providing guidance to first responders in the assessment of stroke patients. This application leverages the world’s largest dataset of stroke patient videos, comprising over 20,000 videos and 6 million images, to train its AI algorithms. The primary end users of this technology include emergency medical services (EMS) personnel and healthcare providers who require rapid and accurate stroke assessments to improve patient outcomes.

AI-Stroke's products are currently utilized in multiple European markets, with ongoing collaborations with various EMS teams across France and broader Europe, thereby targeting regions with significant stroke incidence and healthcare challenges. AI-Stroke generates revenue through partnerships and collaborations with emergency medical services, leveraging a transaction structure that is founded on subscription models or service agreements. These partnerships provide access to the AI-powered diagnostic tools and training modules designed to educate first responders on stroke identification and management. The company’s revenue model involves direct transactions between AI-Stroke and EMS agencies, where fees are charged for the utilization of the mobile application and associated training services.

Specific pricing plans for their products are not detailed, but the transactional framework is centered around delivering value to EMS providers through enhanced diagnostic capabilities that can lead to improved patient care outcomes. In November 2025, AI-Stroke, SAS raised USD 4. 6 mn in Seed funding to support the advancement of its AI-Stroke's clinical validation in Europe. The company aims to expand its product offerings and enhance its application features, focusing on new markets across Europe by 2026, particularly in regions experiencing high stroke incidence.

This funding will be allocated towards research and development to further refine their AI-driven diagnostic tools.